IBRX

Immunitybio Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 7/10
  • Value↓ 0/10
Immunitybio sales and earnings growth
IBRX Growth
Good
  • Revenue Y/Y↑ 668.31%
  • EPS Y/Y↑ 35.59%
  • FCF Y/Y↑ 22.34%
Immunitybio gross and profit margin trends
IBRX Profitability
Good
  • Gross margin ↑ 99.30%
  • EPS margin↓ -310.20%
  • ROIC 5Y↓ -41.68%
Immunitybio net debt vs free cash flow
IBRX Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 2.4
  • Interest coverage↓ -2.1

Immunitybio stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Biotechnology stocks ↗